Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,109.14
(
-0.24%
)
US TECH 100
25,926.40
(
-0.11%
)
Dow Jones
49,442.56
(
-0.01%
)
Brent Oil
90.68
(
-2.14%
)
Bitcoin
75,963.13
(
2.84%
)
News Focus
News Focus
Post# of 517457
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

tredenwater2

Send PM Follow Ignore
Followers 47
Posts 5797
Boards Moderated 0
Alias Born 01/27/2012

tredenwater2

Re: nidan7500 post# 362244

Friday, 06/03/2022 10:57:01 AM

Friday, June 03, 2022 10:57:01 AM

Post# of 517457
Agree, TGD is going for the whole enchilada with each trial supporting the results backwards and forwards applying endpoint efficacy that correlates across different diseases. I believe thats whats holding up the new rare disease ph 3 trial.

Crossing t’s and dotting all the i’s.
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News